The U.S. FDA ordered a pause on clinical trials of a combination therapy for HIV. This won't affect the company's other HIV ...

From parades to parties and everything in between, this guide has all the details you need to show your pride this June. 👇 #bham #pride #June #fun #events #downtownbham GH ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division ...

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

Analysts at Citi said that while the clinical hold impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously expected around 2029/2030, they believe the setback is minor, as it ...

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...

Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) declined 4% on Tuesday after the company announced that the FDA placed clinical holds on studies of several of its HIV drugs.

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

The risk for MACEs was higher among patients with HIV infection receiving abacavir- vs tenofovir-based ART regimens.